OBIO Orchestra BioMed Holdings, Inc.

CIK 0001814114 41 ready 8-Ks latest June 23, 2026, 4:52 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 41

Latest filing June 23, 2026, 4:52 PM ET

Top materiality 0.85

Event mix other_material ×24 · other ×7 · m_and_a ×4

Sentiment 10 pos · 4 neg · 27 neu

Executive change recent →

Recent 8-K filings for OBIO

Highest-materiality recent filing

Orchestra BioMed secures up to $67M in financing from Ligand & Medtronic; cash ~$33.9M

July 31, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

Ligand pays $35M for tiered revenue rights on BACKBEAT & Virtue SAB products; also buys $5M stock and gets 2M-share warrant.
Medtronic provides $20M convertible loan at 11% interest, plus up to $12M equity purchase in subsequent offering.

Read filing →

June 23, 2026, 4:52 PM ET other materiality 0.15 neutral item 5.07

Orchestra BioMed shareholders elect directors, approve ESPP and auditor at 2026 annual meeting

Elected Class III directors: Hochman (39.7M for), Sherman (39.5M), Fain (37.8M); no contested.
February 13, 2026, 6:59 PM ET other material materiality 0.40 neutral item 5.02

Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.

CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure

Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.
November 13, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Orchestra BioMed secures $147M+ funding; BACKBEAT enrollment mid-2026

Over $147M in strategic financing since August 2025; Ligand commits additional $31.6M for royalty interest.
October 30, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Orchestra BioMed posts investor presentation; no new material facts disclosed in filing

Filed investor slide deck under Item 7.01; content not detailed in the 8-K text.
October 28, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 1.02 item 3.02 item 7.01 item 8.01 item 9.01

Orchestra BioMed restructures Terumo deal: $30M total, retains Virtue SAB rights, starts pivotal trial

Terumo pays $10M for ROFR on Virtue SAB coronary rights globally; $20M equity investment via Series A convertible preferred at $100/share.
August 4, 2025, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 7.01 item 8.01 item 9.01

Orchestra BioMed raises ~$56M via public offering and private placement; grants warrant

Public offering of 9,413,637 shares at $2.75/sh + pre-funded warrants for 5,136,363 shares at $2.7499; gross $40M.
July 31, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

Orchestra BioMed secures up to $67M in financing from Ligand & Medtronic; cash ~$33.9M

Ligand pays $35M for tiered revenue rights on BACKBEAT & Virtue SAB products; also buys $5M stock and gets 2M-share warrant.
June 24, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Orchestra BioMed stockholders elect directors, ratify auditor at 2025 annual meeting

Class II directors Chris Cleary, Pamela Connealy, David Pacitti elected to serve until 2028.
April 29, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 7.01 item 8.01 item 9.01

Orchestra BioMed gets FDA Breakthrough Device Designation for AVIM therapy and IDE approval for Virtue SAB trial

FDA granted Breakthrough Device Designation for AVIM therapy; covers >7.7M U.S. hypertension patients.
March 3, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Orchestra BioMed files 8-K furnishing Q1 2025 investor slide presentation

Company filed a slide presentation used at investor conferences as Exhibit 99.1.
February 25, 2025, 6:59 PM ET other material materiality 0.55 neutral item 5.02

Orchestra BioMed approves new cash bonus plan and equity policies for 2025

CEO Hochman and President Sherman eligible for 80% base salary cash bonus; CFO Taylor eligible for 50%.
February 5, 2025, 6:59 PM ET leadership materiality 0.55 positive item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Orchestra BioMed appoints former Medtronic SVP Chris Cleary to board; Dr. Eric Rose resigns as director

Chris Cleary appointed as Class II independent director effective Jan 30, 2025; board expanded to nine.
August 12, 2024, 7:59 PM ET other material materiality 0.55 neutral item 8.01 item 9.01

Orchestra BioMed enters $100M ATM sales agreement with TD Cowen, terminates Jefferies facility

New sales agreement with TD Securities (USA) LLC for up to $100M of common stock in at-the-market offerings.
July 30, 2024, 7:59 PM ET leadership materiality 0.20 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Orchestra BioMed appoints John Mack to board; former Medtronic Cardiac Surgery President

John Mack appointed as Class I director effective July 29, 2024; term expires at 2027 annual meeting.
June 20, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Orchestra BioMed stockholders elect directors and ratify auditor at 2024 Annual Meeting

28.6M shares voted (80% of 35.8M eligible); both Class I directors elected.
June 11, 2024, 7:59 PM ET other material materiality 0.30 neutral item 7.01 item 9.01

Orchestra BioMed holds R&D Day on AVIM Therapy; no new data disclosed

R&D Day held June 11, 2024; presentation covers AVIM Therapy platform.
March 29, 2024, 7:59 PM ET other materiality 0.05 neutral item 8.01

Orchestra BioMed sets first Annual Meeting for June 20, 2024; record date April 26

Annual Meeting scheduled for June 20, 2024; location and time in upcoming proxy statement.
March 7, 2024, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Orchestra BioMed files corporate presentation; no material updates provided

Filed an investor slide presentation used at Q1 2024 conferences.
November 28, 2023, 6:59 PM ET other materiality 0.30 neutral item 1.01 item 9.01 ◈ Material Agreements

Orchestra BioMed amends registration rights agreement, delaying S-1 amendment and effectiveness deadlines

Obligation to amend S-1 deferred to earlier of April 1, 2024 or 15 business days after filing 2023 10-K.
November 14, 2023, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Orchestra BioMed files 8-K furnishing Q4 2023 investor presentation

Company furnished investor presentation as Exhibit 99.1 for use at conferences.
October 10, 2023, 7:59 PM ET other material materiality 0.75 negative item 7.01 item 9.01

Orchestra BioMed postpones Virtue SAB pivotal study to 2024 amid Terumo negotiations

Filed registration statement for resale of shares/warrants; not seeking additional capital.
September 19, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 7.01 item 9.01

FDA grants IDE approval for Orchestra BioMed's BACKBEAT pivotal study of BackBeat CNT in hypertensive pacemaker patients

FDA approved IDE for global pivotal BACKBEAT study evaluating AVIM therapy (BackBeat CNT) for hypertension in pacemaker patients.
July 13, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Orchestra BioMed files 8-K/A to correct prior investor presentation

Amendment corrects the investor presentation originally filed on July 12, 2023; revised Exhibit 99.1 supersedes prior version.
July 12, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Orchestra BioMed furnishes routine investor presentation; no material new information disclosed

Company furnished a slide presentation (Ex 99.1) used at investor conferences and posted on its website.
June 8, 2023, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Orchestra BioMed reports positive clinical data; plans pivotal trials H2 2023

BackBeat CNT showed 8.1 mmHg net reduction in 24-hour aSBP at 6 months and 17.5 mmHg oSBP reduction at 2 years.
June 8, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

Orchestra BioMed appoints Andrew Taylor as CFO, Bill Little as EVP Corp Dev

Michael Kaswan stepped down as CFO effective June 6, 2023; will consult at $36,180/month for up to 6 months.
March 24, 2023, 7:59 PM ET other material materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases

Orchestra BioMed reports 2022 net loss of $33.6M; revenue up to $3.5M from negative prior year

Net loss was $33.6M for 2022 vs $23.0M in 2021; operating expenses rose to $36.2M.
March 13, 2023, 7:59 PM ET other material materiality 0.40 neutral item 7.01 item 8.01 item 9.01

Orchestra BioMed confirms SVB exposure less than 1% of total cash

Less than 1% of total cash, cash equivalents and marketable securities held at Silicon Valley Bank.
January 31, 2023, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.01 item 9.01 item 5.02 item 3.02 item 4.01 item 3.03 item 8.01 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 ◈ executive_change ×9◈ Governance Changes ×4◈ M&A Transactions◈ Material Agreements

Orchestra BioMed completes business combination, 20.2M shares issued, earnout up to 8M shares

Merger closed Jan 26, 2023; each Orchestra share exchanged for 0.465 HSAC2 share; 20.2M new shares issued to Orchestra stockholders.
January 25, 2023, 6:59 PM ET M&A materiality 0.85 positive item 5.02 item 5.07 item 8.01 item 9.01

Health Sciences Acquisitions 2 shareholders approve merger with Orchestra BioMed; closing expected Jan 2023

All 9 proposals approved at Jan 24 EGM, including Merger Agreement, Domestication, and Equity Incentive Plan.
January 24, 2023, 6:59 PM ET other material materiality 0.60 neutral item 8.01

HSAC2 receives redemption requests for 1.6M shares ahead of Jan 24 merger vote

As of Jan 23, 2023, 1,597,888 ordinary shares tendered for redemption by shareholders.
January 24, 2023, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Health Sciences Acquisitions Corp 2 receives Nasdaq delisting notice for failing to hold annual meeting

Received Nasdaq notice on Jan 19, 2023 for failure to hold annual meeting within 12 months after FY2021 end (Dec 31, 2021).
December 21, 2022, 6:59 PM ET other material materiality 0.50 neutral item 3.03

Health Sciences Acquisitions Corp 2 extends business combination deadline to February 6, 2023

Company's directors elected to extend deadline to February 6, 2023, from prior extended date of November 6, 2022.
November 16, 2022, 6:59 PM ET other material materiality 0.60 neutral item 3.03

Health Sciences Acquisitions Corp 2 extends SPAC deadline to Jan 6, 2023

Board elected to extend business combination deadline from Nov 6, 2022 to Jan 6, 2023.
October 31, 2022, 7:59 PM ET other material materiality 0.50 neutral item 3.03

HSAQ board elects to extend business combination deadline to December 6, 2022

Extension adds one month to the prior deadline of November 6, 2022.
October 21, 2022, 7:59 PM ET M&A materiality 0.40 neutral item 1.01 item 9.01

HSAC2 amends backstop and forward purchase agreements with RTW Funds for Orchestra deal

Per-share purchase price under both agreements capped at the shareholder redemption price (not exceeding $10.00).
July 27, 2022, 7:59 PM ET other material materiality 0.60 neutral item 5.07

Shareholders approve extension of business combination deadline to Nov 2022

Extension Proposal approved: 15,084,246 for, 1,365,812 against, 0 abstain.
July 26, 2022, 7:59 PM ET other material materiality 0.75 positive item 8.01

HSAC2 gets redemption requests for 9.2M shares; RTW Funds buys 1M shares at $10.01 to back Orchestra BioMed deal

As of July 22, 2022, shareholders requested redemption of 9,237,883 HSAC2 ordinary shares ahead of July 26 vote on extension to Nov 6, 2022.
July 5, 2022, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 3.02 item 7.01 item 9.01

HSAC2 (HSAQ) enters SPAC merger with Orchestra BioMed; $20M forward purchase agreements, $60M cash condition

Orchestra stockholders receive 0.465 HSAC2 shares per share; earnout up to 8M additional shares at $15/$20 VWAP milestones.
February 10, 2022, 6:59 PM ET other material materiality 0.75 negative item 4.02

Health Sciences Acquisitions 2 restates financial statements due to equity classification error

Audit committee concludes all ordinary shares should be classified as temporary equity, not permanent.